USA Naming a Chief Artificial Intelligence (AI) officer may not be an industry first, but Lilly’s recent creation of the role with the appointment of Thomas Fuchs confirms the solid commitment pharma has already made to introducing AI in processes that range from drug discovery to marketing. AI Leaders Eli…
India Contributing to the October 2024 edition of DIA’s Global Forum magazine, Stephanie Rosner of DIA and Martin Hodosi and Rosanna Lim of Kearney highlight the discussions from DIA’s multistakeholder Responsible AI Solution Room, which focused on cross-sector partnerships for responsible AI use and strategies to mitigate AI risk. Artificial…
USA Troubled gene sequencing firm Illumina has announced a new strategy to accelerate growth. Under the leadership of CEO Jacob Thaysen, Illumina hopes to turn the page on a recent history marked by antitrust issues following its decision to acquire former spin-off company Grail. Illumina’s ambitious new strategy comes after…
Europe This year’s European Society of Medical Oncology (ESMO) was the largest ever. Over 33,000 people attended ESMO Congress 2024 at Barcelona’s cavernous Fira Gran Via conference centre, where 5,000 abstracts were presented and 600 expert speakers took to the stage. The healthcare professionals and cancer drug developers in attendance were…
China Yoshio Uchida, President of Daiichi Sankyo China, outlines the company’s strategic focus on Antibody-Drug Conjugates (ADCs) within China’s oncology market and China’s relevant role in the company’s global R&D operations. He explains how Daiichi Sankyo is addressing the challenges of a dynamic healthcare environment while emphasizing the company’s commitment to…
China A roundup of top stories from China’s pharma industry, including BeiGene’s new US R&D and manufacturing facility; Merck’s purchase of investigational B-cell depletion therapy from Curon Biopharma, and the Chinese approval of AstraZeneca and Daiichi Sankyo’s gastric cancer therapy. China’s BeiGene opens new clinical R&D and biologics manufacturing facility…
Saudi Arabia Attracting, developing, and retaining talented workers – both Saudi and foreign – is perhaps the key sticking point to Saudi Arabia achieving its ambitious transformation targets. Thus far this has involved both ‘carrot’ and ‘stick’ initiatives, ranging from tax incentives and specialised training programs on one side, to mandatory ‘Saudization’…
Saudi Arabia After various leadership roles at Takeda over the course of ten years, Khaled Sary has taken on the position of general manager for the West Gulf cluster, which encompasses Saudi Arabia, Qatar, Oman and Bahrain. In conversation with PharmaBoardroom, Sary discusses the significant growth the Japanese pharma has seen in…
Hong Kong Andrea Chang, general manager of Eisai Hong Kong explains the importance of the firm’s FDA-approved Biogen-partnered Alzheimer’s disease (AD) product, particularly in Hong Kong where some 20 percent of the population is aged 65 or older. In addition, she outlines Eisai’s oncology and neurology-focused portfolio; the potential provided by Hong…
Global The timely and equitable provision of treatment and prevention tools is just one part of the ongoing fight against HIV. Local, national, regional, and international authorities – many of which still labour under misguided preconceptions about people living with HIV – need to come together to effectively buttress the provision…
Spain Some of the biggest stories coming out of Spain’s pharma industry, including Brookfield’s bid for a troubled Grifols; Esteve’s Spanish plant expansion; Rovi’s offers for a potential buyout of its CDMO business, and the EUR 90 million earmarked by Spain’s Ministry of Science, Innovation and Universities (MICIU) to promote biomedical…
Japan A roundup of the most important stories coming out of Japan’s pharma industry, including the sharp increase in deaths linked to Kobayashi supplements; the partnership between Moderna and Mitsubishi Tanabe to jointly promote Moderna’s mRNA respiratory vaccine portfolio; the country’s move to to support domestic antibiotics production; Takeda’s licenscing agreement…
See our Cookie Privacy Policy Here
